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ABSTRACT
Background: Secondary prevention is cost-effective
for cardiovascular disease (CVD), but uptake is
suboptimal. Understanding barriers and facilitators to
adherence to secondary prevention for CVD at multiple
health system levels may inform policy.
Objectives: To conduct a systematic review of barriers
and facilitators to adherence/persistence to secondary
CVD prevention medications at health system level.
Methods: Included studies reported effects of health
system level factors on adherence/persistence to
secondary prevention medications for CVD (coronary
artery or cerebrovascular disease). Studies considered
at least one of β blockers, statins, angiotensin–renin
system blockers and aspirin. Relevant databases were
searched from 1 January 1966 until 1 October 2015.
Full texts were screened for inclusion by 2 independent
reviewers.
Results: Of 2246 screened articles, 25 studies were
included (12 trials, 11 cohort studies, 1 cross-sectional
study and 1 case–control study) with 132 140
individuals overall (smallest n=30, largest n=63 301).
3 studies included upper middle-income countries,
1 included a low middle-income country and 21 (84%)
included high-income countries (9 in the USA). Studies
concerned established CVD (n=4), cerebrovascular
disease (n=7) and coronary heart disease (n=14).
Three studies considered persistence and adherence.
Quantity and quality of evidence was limited for
adherence, persistence and across drug classes. Studies
were concerned with governance and delivery (n=19,
including 4 trials of fixed-dose combination therapy,
FDC), intellectual resources (n=1), human resources
(n=1) and health system financing (n=4). Full prescription
coverage, reduced copayments, FDC and counselling
were facilitators associated with higher adherence.
Conclusions: High-quality evidence on health system
barriers and facilitators to adherence to secondary
prevention medications for CVD is lacking, especially for
low-income settings. Full prescription coverage, reduced
copayments, FDC and counselling may be effective in
improving adherence and are priorities for further
research.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
threat to global health, whether measured by
mortality, morbidity or economic cost.1 The
greatest burden of CVD is in low and
middle-income countries, with crippling
macroeconomic effects.1–4 Health policy
focussing on CVD has become a priority to
policymakers, scientists, health professionals
and patients.5–7
Secondary prevention represents a crucial
and cost-effective component of the response
due to the high absolute risk of recurrent
cardiovascular events in individuals with
established CVD.8 Above and beyond effect-
ive lifestyle interventions (smoking cessation,
physical activity and appropriate diet), there
is high-quality evidence that drug therapy
with aspirin, statins, angiotensin-converting
KEY QUESTIONS
What is already known about this subject?
▸ Despite proven cost-effectiveness of medications
for secondary prevention of cardiovascular
disease, adherence is suboptimal.
What does this study add?
▸ The barriers and facilitators to medication adher-
ence at health system level are poorly charac-
terised, particularly in low-income settings. Full
prescription coverage, reduced copayments,
fixed-dose combination (FDC) therapy and coun-
selling are effective on the basis of existing data,
but further research is needed.
How might this impact on clinical practice?
▸ At health system level, finance mechanisms,
FDC therapy and counselling should be priori-
tised in research and implementation to promote
medication adherence in individuals with cardio-
vascular disease.
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enzyme inhibitors (ACEI) or angiotensin-receptor block-
ers (ARBs) and β blockers is effective in reducing mor-
bidity and mortality from CVD in individuals with
pre-existing CVD.9 Although these medications are off-
patent and should be available at low cost, uptake is sub-
optimal.10 The problem is heightened in the poorest set-
tings, but there are still signiﬁcant gaps even in afﬂuent
countries.11 12
Obstacles to evidence-based secondary CVD preven-
tion are context-speciﬁc, and differences in healthcare
systems between countries of varying incomes are
important contributors to differences in health out-
comes.10 For example, the Population Urban Rural
Epidemiology (PURE) study demonstrated higher CVD
mortality in low-income countries than in high-income
countries, despite a lower risk factor burden in the
former.13 However, there has not been comprehensive
evaluation of barriers and facilitators to medication
adherence for CVD secondary prevention at multiple
health system levels and in diverse ﬁnancial and socio-
cultural settings, which would inform health policy. The
objective of this systematic review was therefore to iden-
tify health system features, programmes or strategies
which act as barriers or facilitators to adherence to
evidence-supported medications for CVD secondary
prevention.
METHODS
A protocol for this study has been published
(PROSPERO 2015: CRD42015019079). We used an
established framework14 to illustrate the health system
and its elements (ﬁgure 1). This conceptual framework
consists of health system ‘inputs’(which include physical,
human, intellectual and social resources) plus compo-
nents and characteristics of delivery, governance and
ﬁnancing.14
Inclusion criteria
We included quantitative and qualitative studies reporting
associations of local, national, regional or international
health system level factors, interventions, policies or
programmes with adherence to medications for the sec-
ondary prevention of CVD (coronary artery or cerebrovas-
cular disease) until 1 October 2015 with no language
restrictions. Included studies had analyses of barriers and
facilitators to adherence or persistence to at least one of β
blockers, statins, angiotensin–renin system blockers and
aspirin. Any outcome measures of adherence (“the extent
to which a patient acts in accordance with the prescribed
interval and dose of a dosing regimen”) or persistence
(“the duration of time from initiation to discontinuation
of therapy”)15 were considered. We excluded studies
reporting prescription and usage alone.
Search strategy
Our search included MEDLINE, EMbase, Cochrane
Library, Psychinfo, Health Systems Evidence, Health
Management Information Consortium (HMIC), Latin
American and Caribbean Health Sciences Literature
(LILACS), Africa-Wide Information and Google Scholar.
We also searched conference proceedings and reference
lists of relevant research articles. We also consulted
experts in health policy regarding access to medicines.
Our search terms and actual strategy are further detailed
in the online supplementary appendix.
Study selection
Each title and/or abstract identiﬁed by the search strat-
egy was independently reviewed for potential eligibility
by two investigators (from AB, MM, KCQ, LN, MS, VP,
JPW, JRFN). Full texts were obtained and further
screened for inclusion by two reviewers. Disagreements
were resolved by a third reviewer.
Data extraction
Prior to data extraction, a validation exercise was con-
ducted to ensure consistency with respect to data
extracted from ﬁve articles. Data were extracted from
each study on study design, setting, methods and out-
comes; health system domains investigated, health
system barriers or facilitators. Data were extracted
according to a ‘health system framework’:14 (1) health
Figure 1 Schematic diagram of health systems conceptual framework (from Maimaris et al14 with permission from PLoS).
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systems delivery; (2) health systems governance; (3)
health systems ﬁnancing; (4) health systems inputs: phys-
ical, human, intellectual and social resources and (5)
outcomes for secondary prevention medications of CVD:
adherence and persistence. Two reviewers (AB and JPW)
checked consistency of inclusion criteria and data extrac-
tion across all included studies. At the data extraction
stage, there was disagreement in 1/25 studies (4.0%),
which was resolved by discussion between AB and JPW.
Assessment of the risk of bias
Included studies were independently assessed for risk of
bias by two reviewers using a framework previously used
for observational study designs in similar systematic
reviews: selection bias, information bias (differential mis-
classiﬁcation and non-differential misclassiﬁcation) and
confounding.14 Risk of bias was assessed as either low,
unclear or high for each domain and overall. The
Cochrane tool for reporting of bias was used for clinical
trials (see online supplementary appendix 2).
Disagreements in classiﬁcation of bias and data extrac-
tion were resolved by a third reviewer (AB or JPW).
Publication bias was assessed by funnel plot analysis.
Conﬂicts of interest were not assessed.
Data synthesis and analysis
Studies were categorised according to health system
domain and setting. ORs were recorded, if reported, as
“OR, 95% conﬁdence interval; p value”. Where possible,
OR or RR was calculated from available data, if not
reported. Reporting complied with standards in
‘Preferred Reporting Items for Systematic Reviews and
Meta-Analyses’ (PRISMA).16 Meta-analysis was not pos-
sible due to heterogeneity of included studies across
multiple domains, including study populations, study
designs, varying deﬁnitions of exposures and outcomes
and analytical strategies.
RESULTS
Figure 2 shows the PRISMA ﬂow chart. A total 2246 arti-
cles were screened by title and abstract. Full texts of 269
of the 2246 articles were assessed for eligibility.
Twenty-ﬁve quantitative and no qualitative studies met
eligibility criteria for this review. Table 1 shows character-
istics of included studies by domains of the conceptual
framework described by Maimaris et al.14 Full details are
in table 2. Online supplementary appendix tables 1a–c
summarise included studies by adherence, persistence
and drug class, respectively. Tables 3 and 4 show risk of
bias assessment for included trials and observational
studies, respectively.
Included study characteristics
In total, there were 132 140 individuals in the 25 studies,
with the smallest study of n=3017 and the largest study of
n=63301.18 Of the 25 included studies, 11 were rando-
mised controlled trials (RCTs);17 19–28 1 was a non-
randomised trial,29 11 were cohort studies,18 30–39 1 was
Figure 2 PRISMA flow chart. CVD, cardiovascular disease. PRISMA, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.
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cross-sectional25 and 1 was case–control.40 Other than 3
studies including upper middle-income countries24 25
and one including a low middle-income country,20 21 of
the 25 studies (84%) were conducted in countries
classiﬁed as high-income countries, 9 of which were in
the USA.17 19 27 30 35 37–40 Studies included individuals
with cerebrovascular disease (n=7),19 21–23 29 30 32 estab-
lished CVD or an estimated 5-year CVD risk of ≥15%
Table 1 Health system arrangements investigated by included studies, classified by health system domain
Health system
framework
domain
Health system
factor being
investigated
Number of
studies
Number of studies and
study designs Setting of studies (countries)
Governance and
delivery
Physician-led
education
1 RCT (1) UK (1)21
Nurse-led education 3 RCT (2) Denmark (1),22 UK (1)23
Cohort (1) USA/Canada (1)39
Pharmacy-led
education
2 RCT (1) USA (1)17
Non-randomised trial (1) Germany (1)29
Comprehensive
education
programme
2 RCT (1) Turkey (1)24
Cohort (1) France (1)36
Hospital-level quality
improvement
4 RCT (1) USA (1)19
Cohort (2) USA (1)30 Canada (1)31
Case–control (1) USA (1)41
Routine place of care 1 Cohort (1) Sweden (1)32
Generic versus
branded drugs
1 Cohort (1) USA (1)37
Complexity of
treatment regimen
1 Cross-sectional (1) Argentina/Brazil/Italy/Paraguay/
Spain (1)25
FDC 4 RCT (4) India/Europe (1),20 Australia/New
Zealand (1),26 New Zealand (1),28
Argentina/Brazil/Italy/Paraguay/
Spain (1)25
All governance and
delivery studies
19 RCT (10), non-randomised
trial (1), cohort (6),
cross-sectional (1), case–
control (1)
USA (5), Canada (1), USA/Canada
(1), UK(2), Germany (1), Sweden
(1), Turkey (1), France (1),
Denmark (1), India/Europe (1),
Australia/New Zealand (1), New
Zealand (1), Argentina/Brazil/Italy/
Paraguay/Spain (2)
Human
resources
Undergraduate
training of physicians
1 Cohort (1) Canada (1)18
All human resources
studies
1 Cohort (1) Canada (1)
Intellectual
resources
Education of
physicians
1 Cohort (1) Israel (1)33
All intellectual
resources studies
1 Cohort (1) Israel (1)
Health system
financing
Copayments for
medical care
2 Cohort (2) USA (1),35 Austria (1)34
Insurance and
prescription cost
assistance
2 Cohort (1) USA (1)38
RCT (1) USA (1)27
All financing studies 4 RCT (1), cohort (3) USA (3), Austria (1)
Physical
resources
All physical
resources studies
0
Social resources All social resources
studies
0
Italics denote the total number of studies under a particular health system domain.
RCT, randomised controlled trial.
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Table 2 Summary of findings of studies examining the associations of barriers/facilitators and adherence/persistence
Barriers/
facilitators
Study (author,
year, setting) Context Study design
Sample
size Study details Outcome
Relevant findings (95%
CIs given where available
and in italics when
p<0.05)
Patient
counselling
O’Carroll, 2013
(UK)21
First stroke/TIA RCT 62 Intervention=physician-led
counselling sessions aimed at
increasing adherence
Adherence to
antihypertensive
medication at
3 months
Electronic pill
count and
self-report
Intervention versus control:
by electronic pill count,
percentage of doses taken
on schedule—96.8% vs
87.4%, mean difference
9.8%, 95% CI 0.2 to 16.2;
p=0.048
Self-report highly correlated
with electronic pill count
Hornnes, 2011
(Denmark)22
Acute stroke/TIA RCT 349 Intervention=four home visits
by a nurse with individually
tailored counselling on a
healthy lifestyle
Adherence to
antihypertensive
therapy at 1 year
Self-report
Intervention versus control:
98% vs 99%, OR 0.88,
95% CI 0.54 to 1.44;
p=0.50
Maron, 2010
(USA and
Canada)39
Stable CHD Prospective cohort 2287 Nurse-led case management
nested in the Clinical
Outcomes Utilizing
Revascularization and
Aggressive Drug Evaluation
(COURAGE) Trial. CVD drugs
provided at no cost
Adherence and
persistence to 4D
at 5 years
Self-report
Persistence increased from
baseline to 5 years as
follows: antiplatelets 87% to
96%, (OR 3.58, 95% CI
2.48 to 5.18); β blockers
69% to 85% (OR 2.54, 2.06
to 3.15); ARBs 46% to 72%
(OR 3.02, 2.53 to 3.60),
statins 64% to 93% (OR
7.51, 5.67 to 9.94), 4D 28%
to 53% (OR 2.90, 95% CI
2.44 to 3.43) (all p<0.001).
Adherence was 97% at
6 months and 95% at
5 years
McManus,
2009 (UK)23
Stroke in hospital RCT 102 Intervention=3 months
nurse-led health counselling
with written and verbal
information on lifestyle, and
check of medication
concordance
Adherence and
persistence to 4D
at 3 years
Self-report
Persistence: 95% vs 89%,
OR 3.00, 0.57 to 15.7
(p=0.19) for antiplatelets
97% vs 95%, OR 1.02, 0.55
to 1.91 (p=0.95) for
antihypertensives
88% vs 89%, OR 1.03, 0.25
to 4.14 (p=0.97) for statins
Adherence to 4D: 78% vs
92%, OR 0.30, 0.07 to 1.24
(p=0.10)
Continued
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Table 2 Continued
Barriers/
facilitators
Study (author,
year, setting) Context Study design
Sample
size Study details Outcome
Relevant findings (95%
CIs given where available
and in italics when
p<0.05)
Faulkner, 2000
(USA)17
CABG RCT 30 Intervention=weekly
pharmacist-led telephone
contact for 12 weeks
Adherence to
lovastatin at
1 year and
2 years
Prescription fill
rate
Intervention versus control:
67% vs 33%; p<0.05 at
1 year and 60% vs 27%;
p<0.05 at 2 years (χ2 test
reported)
At 1 year, OR 4.00, 0.88 to
18.26; p=0.07, and at
2 years, OR 4.13, 0.88 to
19.27; p=0.07
Hohmann,
2009
(Germany)29
Ischaemic stroke/
TIA in hospital
Non-randomised,
controlled
intervention trial
255 Intervention=hospital
pharmacist counselling before
discharge and plan for
outpatient care plus
counselling by community
pharmacists
Persistence to
aspirin and
clopidogrel at
1 year
Self-reported and
GP-reported
Intervention: 38.7% vs
32.7%, OR 1.30, 0.73 to
2.31; p=0.37 for aspirin and
26.7% and 30.1%, OR
0.85, 0.46 to 1.57; p=0.60
for clopidogrel
Lafitte, 2009
(France)36
ACS in hospital Prospective cohort 660 3 months after discharge for
ACS, consecutive patients
were invited to join a
comprehensive risk factor
management programme
Persistence to 4D
at 20 months
(mean follow-up)
Self-report
At follow-up and baseline,
respectively (no control
group reported): 86% vs
98% for β blocker or a
calcium antagonist, 88% vs
94% for statin, 96% vs
100% for antiplatelet, 62%
vs 82% for ACEI/ARB, 76%
vs 92% for 4D
Yilmaz, 2005
(Turkey)24
Secondary
prevention in
hospital
RCT 202 Intervention=counselling
regarding efficacy,
pharmacokinetic profile, and
side effects of ongoing statins
Persistence to
statin therapy at
15 months
(median
follow-up)
Self-report
62.7% vs 46%; OR=1.98,
1.13 to 3.47; p=0.017
Hospital quality
improvement
programmes
Bushnell, 2011
(USA)30
Ischaemic stroke/
TIA in hospital
Retrospective
cohort
2457 Guideline implementation in
the Adherence eValuation After
Ischemic stroke–Longitudinal
(AVAIL) Registry in a sample of
hospitals participating in the
Get With The Guidelines—
Stroke program
Persistence and
adherence to 4D
at 1 year
Self-report
Persistence and adherence
associated with: number of
medications prescribed at
discharge (OR=1.08, 1.04
to 1.11; p<0.001 per 1
decrease); and follow-up
appointment with GP
(OR=1.72, 1.12 to 2.52;
p=.0.006)
Continued
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Table 2 Continued
Barriers/
facilitators
Study (author,
year, setting) Context Study design
Sample
size Study details Outcome
Relevant findings (95%
CIs given where available
and in italics when
p<0.05)
Jackevicius,
2008
(Canada)31
AMI in hospital Retrospective
cohort
4591 Quality improvement of care in
the Enhanced Feedback for
Effective Cardiac Treatment
(EFFECT) study registry in
Ontario
Adherence to 4D
at 120 days
Prescription fill
rate
Predischarge medication
counselling: OR 1.61, 1.26
to 2.04; p=0.0001
Cardiologist (vs GP) as
doctor responsible for
patient’s care: OR 1.80,
1.34 to 2.43; p=0.0001.
Teaching versus other
hospital: OR 1.35,0.93 to
1.97; p=0.11
Johnston, 2010
(USA)19
Ischaemic stroke
in hospital
RCT 3361 Intervention: assistance in the
development and
implementation of standardised
stroke discharge orders
Adherence to
statin at 6 months
Prescription fill
rate
Intervention versus
non-intervention hospitals,
At hospital level: OR, 1.26;
0.70 to 2.30; p=0.36.
At individual level: OR,
1.29; 1.04 to 1.60; p=0.02
Khanderia,
2005 (USA)40
CABG in hospital Retrospective
case–control
403 A physician education protocol
to implement statin in all
patients admitted for CABG
Persistence to
statins at 6
months
Self-report
Intervention versus control:
67% vs 58%, OR 1.49, 0.88
to 2.55; p=0.14
Site of care and
home
circumstances
of patients
Glader, 2010
(Sweden)32
Acute stroke in
hospital
Prospective cohort 21 077 A 1-year cohort (September
2005–August 2006) from the
Swedish Stroke Register
Persistence with
4D at 1 year
Prescription fill
rate
Institutional living correlated
with persistence for all drug
classes (p=0.001). Stroke
unit care was associated
with persistence for statins
(p=0.007).
Support by next-of-kin
associated with persistence
for antihypertensives
(p=0.001)
Generic versus
branded drugs
O’Brien, 2015
(USA)37
NSTEMI in
hospital
Retrospective
cohort
1421 NSTEMI patients ≥65 years old
discharged on a statin in 2006
from USA hospitals
Adherence to
statins at 1 year
Prescription refill
rate
Generic versus brand
users: 86.0% (IQR=42.6–
97.2%) vs 84.1%
(IQR=53.4–97.0%)),
(p=0.97)
Continued
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Table 2 Continued
Barriers/
facilitators
Study (author,
year, setting) Context Study design
Sample
size Study details Outcome
Relevant findings (95%
CIs given where available
and in italics when
p<0.05)
Complexity of
treatment
regimen
Castellano,
2014
(Argentina,
Brazil, Italy,
Paraguay and
Spain)25
Aged >40 years
with AMI in last
2 years
Cross-sectional
study
2118 In a single visit, data was
gathered to estimate
prescription, adherence and
barriers to adherence for
aspirin, ACEIs, β blockers and
statins
Adherence to 4D
Self-report
Non-adherence was
associated with age
<50 years (OR 1.50, 95%
CI 1.08 to 2.09; p=0.015),
depression (OR 1.07, 95%
CI 1.04 to 1.09; p<0.001),
being on a complex
medication regimen (OR
1.42, 95% CI 1.00 to 2.02:
p=0.047) and lower level of
social support (OR 0.94
0.92 to 0.96; p<0.001)
FDC Thom, 2013
(India,
Europe)20
High CV risk RCT 1698 Intervention=FDC (containing
either: 75 mg aspirin, 40 mg
simvastatin, 10 mg lisinopril,
and 50 mg atenolol or 75 mg
aspirin, 40 mg simvastatin,
10 mg lisinopril and 12.5 mg
hydrochlorothiazide)
Adherence to 4D
at 15 months
Self-report
FDC versus separate
medications: RR 1.29, 95%
CI 1.22 to 1.36; p<0.0001
FDC Castellano,
2014
(Argentina,
Brazil, Italy,
Paraguay and
Spain)25
Aged >40 years
with AMI within
last 2 years.
RCT 695 Intervention=FDC (containing
aspirin 100 mg, simvastatin
40 mg and ramipril 2.5, 5 or
10 mg)
Adherence at
9 months
Self-report and pill
count
FDC versus separate
medications: RR 1.24, 95%
CI 1.06 to 1.47; p=0.009
Selak, 2014
(New
Zealand)28
High CV risk RCT 233 Intervention=FDC (with two
versions available: aspirin
75 mg, simvastatin 40 mg and
lisinopril 10 mg with either
atenolol 50 mg or
hydrochlorothiazide 12.5 mg)
Adherence to 4D
at 12 months
Self-report
FDC versus separate
medications: RR 1.50, 95%
CI 1.25 to 1.82; p<0001
Patel, 2015
(Australia, New
Zealand)26
High CV risk RCT 381 Intervention=FDC (containing
aspirin 75 mg, simvastatin
40 mg, lisinopril 10 mg and
either atenolol 50 mg or
hydrochlorothiazide 12.5 mg)
Adherence to 4D
at 18 months
(median
follow-up)
Self-report
FDC versus separate
medications: RR 1.26, 95%
CI 1.08 to 1.48; p<0001
Continued
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Table 2 Continued
Barriers/
facilitators
Study (author,
year, setting) Context Study design
Sample
size Study details Outcome
Relevant findings (95%
CIs given where available
and in italics when
p<0.05)
Physician
education/
training
Ko, 2005
(Canada)18
AMI aged
≥65 years in
hospital
Retrospective
cohort
63 301 Evaluation on whether care by
International medical graduates
(IMGs) is a determinant of poor
persistence and worse
outcomes after AMI versus
care by Canadian medical
graduates (CMGs)
Persistence to 4D
at 90 days
Prescription refill
Adjusted OR(Canadian/
IMG): aspirin 1.00 95% CI
(0.94 to 1.06); BB 1.01
(0.94 to 1.08); ACEI 1.07
(1.01 to 1.14); statins 1.10
(1.01 to 1.20)
Harats, 2005
(Israel)33
CHD in hospital Cross-sectional
and prospective
Cohort
2994 Brief educational sessions with
physicians to review National
guidelines to ascertain
physician’s awareness
Persistence to
statins at 8 weeks
Self-report
Intervention versus control:
57% vs 45%. (p<0.001)
Copayments for
medical care
Winkelmayer,
2007
(Austria)34
AMI in hospital Retrospective
cohort
4105 The association between
copayments and outpatient use
of β blockers, statins, and
ACEI/ARB in Austrian MI
patients
Adherence at
120 days
Prescription refill
rate
Adherence (waived
copayments versus
copayment): OR 1.35; 95%
CI 1.10 to 1.67 for ACEI/
ARB, OR 1.09; 0.89 to
1.35) for β blocker and OR
1.09;0.89 to 1.34 for statin
Ye, 2007
(USA)35
CHD and
hospital-initiated
statin
Retrospective
cohort
5548 Databases containing inpatient
admission, outpatient,
enrollment and pharmacy
claims from 1999 to 2003 to
study associations with
copayments
Adherence to
statins at 1 year
Prescription refill
rate
Adherence (copayment
≥US$20 vs copayment <US
$10): OR 0.42; 95% CI 0.36
to 0.49
Insurance and
prescription
cost assistance
Choudhry,
2011 (USA)27
AMI in hospital RCT 5855 Intervention=full prescription
coverage by insurance-plan
sponsor
Adherence to 4D
at 394 days
(median
follow-up)
Prescription refill
rate
Full-coverage versus usual
coverage: OR 1.41, 95% CI
1.18 to 1.56; p<0.001 for
4D and p<001 for all
individual drug classes
Mathews, 2015
(USA)38
ACS in hospital Prospective cohort 7955 Within the Treatment with
Adenosine Diphosphate
Receptor Inhibitors:
Longitudinal Assessment of
Treatment Patterns and Events
after Acute Coronary
Syndrome (TRANSLATE-ACS)
study
Persistence to 4D
at 6 months
Self-report
Non-persistence less likely
with private insurance (OR
0.85, 95% CI 0.76 to 0.95),
prescription cost assistance
(OR 0.63, 0.54 to 0.75),
and clinic follow-up
arranged predischarge (OR
0.89, 0.80 to 0.99)
4D, secondary prevention drugs for CVD, namely, antiplatelets, β blockers, angiotensin-converting enzyme inhibitor or angiotensin-receptor blockers and statins; ACEI, angiotensin-converting
enzyme inhibitor; AMI, acute myocardial infarction; ACS, acute coronary syndrome; ARB, angiotensin-receptor blocker; CABG, coronary artery bypass graft; CHD, coronary heart disease;
CVD, cardiovascular disease; FDC, fixed-dose combination therapy; GP, general practitioner; NSTEMI, non ST-elevation myocardial infarction; RCT, randomised controlled intervention trial;
RR, relative risk; TIA, transient ischaemic attack.
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Table 3 Risk of bias of included studies (trials)
Study
(author, year,
setting) Context Study design
Random
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants and
personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome
data
(attrition
bias)
Selective
reporting
(reporting
bias)
Risk of bias
assessment
O’Carroll,
2013 (UK)21
First stroke/
TIA
RCT + + - - + + High risk of
bias:
performance
and detection
Hornnes, 2011
(Denmark)22
Acute
stroke/TIA
RCT + + − + + + High risk of
bias:
performance
McManus,
2009 (UK)23
Stroke in
hospital
RCT + + + + + + Low risk of
bias
Faulkner, 2000
(USA)17
CABG RCT + − − − + + High risk of
bias: selection,
performance
and detection
Hohmann,
2009
(Germany)29
Ischaemic
stroke/TIA in
hospital
Non-randomised
controlled
intervention trial
− − − − + + High risk of
bias: selection,
performance
and detection
Yilmaz, 2005
(Turkey)24
Secondary
prevention in
hospital
RCT ? − − − + + High risk of
bias: selection,
performance
and detection
Johnston,
2010 (USA)19
Ischaemic
stroke in
hospital
RCT + + − − + + High risk of
bias:
performance
and detection
Thom, 2013
(India,
Europe)20
High CV risk RCT + + ? ? + + Unclear risk of
bias:
performance
and detection
Castellano,
2014
(Argentina,
Brazil, Italy,
Paraguay and
Spain)25
Aged
>40 years
with AMI
within last
2 years
RCT + + ? ? + + Unclear risk of
bias:
performance
and detection
Selak 2014
(New
Zealand)28
High CV risk RCT + + + + + + Low risk of
bias
Continued
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(n=4)20 24 26 28 and coronary heart disease (from stable
CHD, to acute myocardial infarction (AMI), to coronary
artery bypass graft (CABG)) (n=14).17 18 25 27 31 33–40
Thirteen studies included aspirin, β blocker, ACEI/
ARB, and statin.18 20 23 25–28 30–32 36 38 39 Two studies
investigated antihypertensive medication, including β
blockers and ACEI/ARB,21 22 and seven studies included
only statins.17 19 24 33 35 37 40 One study focused on anti-
platelet drugs including aspirin.29 One study investigated
β blockers, statins and ACEI/ARB34 and one considered
aspirin, ACEI and statin25 (see online supplementary
appendix table 2c).
In 16 studies, indirect measures of adherence were
employed: prescription reﬁll rates (medication posses-
sion ratio (MPR),27 35 proportion of days covered
(PDC)37 and other measures),17 19 31 34 electronic pill
bottle count,21 manual pill count25 and self-
report.20 22 23 25 26 28 39 Persistence was measured in 11
studies, by self-report23 24 29 30 33 36 38–40 or prescription
reﬁll.18 32 Three studies considered persistence and
adherence.23 30 39
Nineteen of 25 included studies were concerned with
governance and delivery (table 1).17 19–26 28–32 36 37 39 40
Only one study, based in Canada, considered human
resource implications on adherence to medication in a
retrospective cohort design.18 Only one study considered
intellectual resources (impact of physician education on
medication adherence) in patients admitted with CHD
in Israel.33 Health ﬁnancing was considered in four
studies in the USA27 35 38 and Austria,34 respectively. No
studies examined the role of physical or social resources
in medication adherence.
Quality of included studies
Only 2 of the 12 included trials were deemed to have
low risk of bias,23 28 and 2 had an unclear degree of
bias.20 25 Remaining trials had high risk of bias in one or
several domains, most commonly due to lack of blinding
of participants, personnel or outcomes (table 3). Three
included observational studies had low risk of bias in all
domains30–32 (table 4). Although meta-analysis was not
undertaken, funnel plot asymmetry suggests possible
publication bias (see online supplementary appendix
ﬁgure 1).
Barriers
Complexity of treatment regimen
A cross-sectional study of individuals with myocardial
infarction (MI) in the last 2 years in South America/
Europe showed that taking more than 10 pills (p=0.047)
and a complex regimen (eg, taking medications other
than orally) (p=0.017) were associated with self-reported
non-adherence. However, only a complex regimen was
independently predictive of non-adherence (OR 1.42,
1.00 to 2.02; p=0.047).25
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Copayments for medical care
Two retrospective cohort studies investigated the impact
of copayments on adherence. Both studies had low risk
of bias but high risk of confounding. Among 4105
patients with acute MI in Austria,34 those with waived
copayments had higher persistence at 120 days for
ACEI/ARB than those with copayments (OR 1.35, 95%
CI 1.10 to 1.67), but β blocker (OR 1.09, 0.89 to 1.35)
or statin use (OR 1.09, 0.89 to 1.34) did not differ
between these groups. The second US study of CHD
patients35 found that compared with copayment <US
$10, copayment ≥US$20 was associated with lower per-
sistence at 1 year for statins (OR 0.42; 0.36 to 0.49,
p<0.001).
Insurance and prescription cost assistance
A US-based prospective cohort study of 7955 MI patients
in 216 hospitals showed that non-persistence to second-
ary prevention medications was less likely with private
insurance (OR 0.85, 95% CI 0.76 to 0.95) and prescrip-
tion cost assistance (OR 0.63, 95% CI 0.54 to 0.75).38 A
US-based RCT included 5855 individuals post-MI, rando-
mised to full or usual prescription coverage.27 Full
adherence was higher with full prescription coverage for
all medication classes (OR 1.41, 1.18 to 1.67; p<0.001).
Increased adherence to all three medications for the
patient subgroup undergoing CABG was found, post hoc
(OR 1.67, 95% CI 1.04 to 2.67; p=0.03).41
Facilitators
Patient counselling
Patient counselling was the most investigated facilitator
of adherence/persistence (table 2). Only one study
investigated impact of physician-led counselling follow-
ing ﬁrst stroke/transient ischaemic attack (TIA). This
UK RCT included 62 individuals, with high risk of bias
overall21 (table 3). At 3 months, adherence to antihyper-
tensive medication was higher in the intervention group
for doses taken on schedule (ie, mean difference, 9.8%;
95% CI (0.2 to 16.2); p=0.048).
Three studies considered nurse-led interventions in a
total of 2738 individuals in Denmark, the USA/Canada
and the UK, respectively,22 23 39 with high risk of bias in
the Danish study and high risk of confounding in the
American study (table 3). The Danish study randomised
stroke/TIA patients to four home visits with nurse-led
counselling, ﬁnding no difference in self-reported
adherence at 1 year between intervention and control
groups (98% vs 99%, respectively, OR 0.88, 95% CI 0.54
to 1.44; p=0.50).22 The North American study assigned
nurse case managers to patients with stable CHD over a
5-year period, nested within a trial of percutaneous cor-
onary intervention and optimal medical therapy versus
optimal medical therapy alone.39 Persistence increased
from baseline to 5 years across all drug categories,
including all four drugs together (28% to 53%, OR 2.90,
95% CI 2.44 to 3.43; p<0.001). Self-reported adherence
was not different between groups (97% at 6 months and
95% at 5 years, respectively). Lack of a control group
limited study ﬁndings. In the UK-based RCT,23 patients
who had stroke were randomised to nurse-led counsel-
ling sessions for 3 months. At 3 years, persistence and
adherence were not different between groups (table 2).
Two studies investigated pharmacist-led counselling of
patients: one RCT in the USA17 and one non-
randomised trial in Germany.29 The US trial included 30
patients following CABG, randomised to weekly pharma-
cist telephone calls for 3 months or usual care.
Adherence to statins was higher in the intervention
group versus the control group at 1 year (71% vs 47%;
p<0.05) and at 2 years (63% vs 39%) as measured by
prescription reﬁll, using the χ2 test. However, the effect
was not statistically signiﬁcant using ORs at 1 year (OR
4.00, 0.88 to 18.26; p=0.07) or 2 years (OR 4.13, 0.88 to
19.27; p=0.07). In the German trial, a hospital pharma-
cist delivered predischarge counselling to 255 stroke/
TIA patients was compared with usual care. At 1 year,
persistence was 38.7% vs 32.7%, OR 1.30, 0.73 to 2.31;
p=0.37) for aspirin and 30.1% and 26.7% (p=0.60) for
clopidogrel, in intervention versus control groups,
respectively.
Two studies reported on the delivery of comprehensive
health counselling in hospital-based patients.24 36 In a
secondary prevention population of 202 individuals
already on statins, a Turkish RCT24 found that compre-
hensive counselling was associated with increased adher-
ence compared with usual care (62.7% vs 46%;
OR=1.98; p=0.017) after a median follow-up of
15 months. Bias due to contamination was likely as
patients were already taking statins. In France, a pro-
spective cohort study without the control group invited
660 patients 3 months after acute coronary syndrome for
comprehensive risk factor management with a cardiolo-
gist.36 Persistence was 86% vs 98% for β blocker/calcium
antagonist, 88% vs 94% for cholesterol-lowering medica-
tion, 96% vs 100% for antiplatelet, 62% vs 82% for
ACEI/ARB and 76% vs 92% for antiplatelet, β blocker
and cholesterol-lowering medications combined at
follow-up (mean 20 months) and baseline, respectively
(all p<0.0001). This study had high risk of bias across
the domains of differential misclassiﬁcation, non-
differential misclassiﬁcation and confounding.
Hospital-level quality improvement
In this section, studies at the level of the hospital or a
whole health system were considered. All four studies of
hospital-level quality improvement were conducted in
North America (three in the USA,19 30 40 one in
Canada)31 with one RCT, two cohort studies and one
case–control study (table 1). The case–control study and
RCT had high risk of bias (tables 3 and 4). The RCT
found that hospital-level assistance in the development
and implementation of standardised stroke discharge
orders was not associated with improved adherence over
12 months at the hospital level (57.3% vs 62.9%; OR
1.26, 95% CI 0.70 to 2.30; p=0.36), although there was
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improvement in adherence to statins at the individual
level (OR 1.29, 1.04 to 1.60; p=0.02).19
One retrospective cohort study in acute MI patients in
Canada31 showed that predischarge medication counsel-
ling (76.0% vs 64.8%; OR 1.61, 1.26 to 2.04; p=0.0001)
and having a cardiologist (vs general practitioner)
responsible for patient care were associated with adher-
ence at 120 days postdischarge (34.5% vs 25.4%; OR
1.80, 1.34 to 2.43; p=0.0001), with no association with
treatment at a teaching hospital (14.8% vs 11.8%; OR
1.35, 0.93 to 1.97; p=0.11). In a retrospective cohort
study of stroke/TIA patients in the USA,30 12-month per-
sistence with secondary prevention medications was asso-
ciated with fewer medications (OR=1.04, 1.02 to 1.06,
p<0.001 per one medication decrease); in-patient
rehabilitation (13.4% vs 21.6%; OR=0.57, 0.43 to 0.76,
p<0.001); primary care follow-up (92.1% vs 88.4%;
OR=1.47, 1.05 to 2.07, p=.0.027) and neurology
follow-up (43.3% vs 35.0%; OR=1.20, 1.03 to 1.41,
p=0.023). Fewer medications (OR=1.08, 1.04 to 1.11,
p<0.001 per 1 decrease) and primary care follow-up
(OR=1.72, 1.12 to 2.52, p=0.006) were associated with
persistence and adherence. A retrospective case–control
study of CABG patients found that a physician education
protocol was not associated with improved adherence to
statins at 6 months.40
Site of care and home circumstances of patients
A Swedish prospective cohort study of patients who had
stroke32 found that institutional living was correlated
with persistence of all secondary prevention medications
(p=0.001). Stroke unit care was associated with persist-
ence for statins (p=0.007), and next-of-kin support was
associated with persistence for antihypertensives
(p=0.001).
Generic versus branded medication prescription
A US retrospective, hospital-based cohort study of indivi-
duals post-NSTEMI (non-ST elevation myocardial infarc-
tion) investigated 1-year statin adherence by prescription
of generic versus branded medications.37 Although
patient copayment amounts were higher for brand
Table 4 Risk of bias of included observational studies
Study (author, year,
setting) Context Study design
Bias
Risk of bias assessmentS DM ND C
Maron, 2010 (USA and
Canada)39
Stable CHD Prospective cohort Low Low Low High High risk of confounding
Lafitte, 2009 (France)36 ACS in hospital Prospective cohort High High High High High risk of bias
Bushnell, 2011 (USA)30 Ischaemic
stroke/TIA in
hospital
Retrospective cohort Low Low Low Low Low risk of bias
Jackevicius, 2008
(Canada)31
AMI in hospital Retrospective cohort Low Low Low Low Low risk of bias
Khanderia, 2005
(USA)40
CABG in
hospital
Retrospective case–
control
High Low Low High High risk of bias
Glader, 2010
(Sweden)32
Acute stroke in
hospital
Prospective cohort Low Low Low Low Low risk of bias
O’Brien, 2015 (USA)37 NSTEMI in
hospital
Retrospective cohort Low Low Low High Low risk of bias, but high
risk of confounding
Castellano, 2014
(Argentina, Brazil, Italy,
Paraguay and Spain)25
Aged >40 years
with AMI within
last 2 years
Cross-sectional
study
High Low Low High High risk of bias—
selection bias and
confounding
Ko, 2005 (Canada)18 AMI aged
≥65 years in
hospital
Retrospective cohort Low Low Low Unclear Low risk of bias but
unclear risk of
confounding
Harats, 2005 (Israel)33 CHD in hospital Cross-sectional then
prospective cohort
Low High Low High High risk of bias due to
differential
misclassification and
confounding
Winkelmayer, 2007
(Austria)34
AMI in hospital Retrospective cohort Low Low Low High Low risk of bias but high
risk of confounding
Ye, 2007 (USA)35 CHD and
initiated statin in
hospital
Retrospective cohort Low Low Low High Low risk of bias but high
risk of confounding
Mathews, 2015
(USA)38
ACS in hospital Prospective cohort Low Low Low High Low risk of bias but high
risk of confounding
Bias: S, selection; DM, differential misclassification; ND, non-differential misclassification; C, confounding. AMI, acute myocardial infarction;
CABG, coronary artery bypass graft; CHD, coronary heart disease; NSTEMI, non-ST elevation myocardial infarction; ACS, acute coronary
syndrome; TIA, transient ischaemic attack.
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versus generic statins (median=US$25 vs US$5,
p<0.001), there was no statistically signiﬁcant difference
in adherence over 1 year (71.5% vs 68.9%, unadjusted
OR 1.15, 95% CI 0.96 to 1.37; p=0.97).
Fixed-dose combination therapy
Four RCTs examined ﬁxed-dose combination therapy
(FDC).20 25 26 28 One RCT in Europe and India in 1698
individuals with established CVD demonstrated that FDC
(either aspirin/simvastatin/lisinopril/atenolol or hydro-
chlorothiazide) was associated with higher self-reported
adherence than routine therapy (RR 1.29, 95% CI 1.22
to 1.36; p<0.0001).20 In 695 individuals in Argentina,
Brazil, Italy, Paraguay and Spain, FDC (containing
aspirin/simvastatin/ramipril) was compared with the
three drugs given separately in individuals with MI in
the last 2 years.25 Adherence (by self-report and pill
count) was higher with FDC (RR 1.24, 95% CI 1.06 to
1.47; p=0.009). A trial in Australia/New Zealand com-
pared FDC (containing aspirin/simvastatin/lisinopril/
atenolol or hydrochlorothiazide) with usual care in 381
individuals with established CVD. Self-reported adher-
ence was higher with FDC (RR 1.49; 95% CI 1.30 to
1.72; p<0.0001).26 A further trial in New Zealand com-
pared FDC (containing aspirin/simvastatin/lisinopril/
atenolol or hydrochlorothiazide) with usual care in 233
individuals with established CVD.28 Self-reported adher-
ence was greater with FDC (RR 1.75, 95% CI 1.52 to 2.03,
p<0.001). Of the four trials, only the New Zealand RCT
had low risk of bias with the other three having unclear
risk of performance and detection biases (table 3).
Physician education/training
Among 63 301 acute MI patients, there was no signiﬁ-
cant difference in medication persistence at 90 days
between patients treated by non-Canadian versus
Canadian graduates for aspirin (OR 1.00, 0.94 to 1.06)
or β blocker (OR 1.01, 0.94 to 1.08). There was
increased persistence in the non-Canadian medical
graduate-treated group for ACEI (OR 1.07, 1.01 to 1.14)
and statins (OR 1.10, 1.01 to 1.20), compared with
patients treated by Canadian medical graduates.18 The
relevance of these ﬁndings is reduced by the low ORs, a
plausible mechanism for differential effect on different
drugs and the unclear risk of confounding. In a hospital-
based study of CHD patients in Israel, an educational
programme for physicians increased self-reported per-
sistence to statins at 8 weeks follow-up (57% vs 45% at
follow-up; p<0.001). However, there was high risk of dif-
ferential misclassiﬁcation bias and confounding.
Persistence and adherence
Adherence was assessed across studies from 3 months to
5 years (see online supplementary appendix table 1a).
The three studies with follow-up ≥2 years did not show
increased adherence.17 23 39 FDC consistently increased
adherence across four RCTs with follow-up at between 9
and 18 months.20 25 26 28 Copayments, insurance and
prescription coverage were all associated with increased
adherence from 120 days to 1 year.27 34 35
Two RCTs23 24 and one non-randomised trial29 had
persistence outcomes, and only one RCT showed a posi-
tive impact of counselling on statin persistence at
15 months median follow-up24 (see online
supplementary table 1b). The only trial considering per-
sistence and adherence did not show effect on these out-
comes.23 Nurse-led case management was associated
with increased persistence at 5 years but not increased
adherence.39
Different medication classes
Of the studies considering all four classes of secondary
prevention medications, FDC and prescription coverage
were supported by RCT evidence.20 26–28 The two RCTs
of counselling on antihypertensive therapy had conﬂict-
ing ﬁndings.21 22 Overall, there were insufﬁcient
numbers of studies considering individual classes of
medications and lack of consistency of ﬁndings within
the existing studies to suggest varying effects of interven-
tions across different classes of medications.
DISCUSSION
The World Heart Federation’s ‘25 by 25’ strategy to
tackle the CVD epidemic and speciﬁcally its recent
roadmap for secondary prevention give context to our
four key ﬁndings.12 First, at health systems level, there is
lack of high-quality evidence on barriers and facilitators
(especially from low and low-middle income countries)
to adherence and persistence for the most well-
established therapies available for secondary prevention
of CVD. The only barriers with available data were com-
plexity of treatment regimen and health ﬁnancing.
Several potential facilitators have been considered but
not in a coordinated manner for adherence and persist-
ence, or different classes of drugs. Second, FDC therapy
is associated with increased adherence. Third, reduced
copayments and full prescription coverage were asso-
ciated with increased adherence and persistence. Finally,
counselling of patients whether by doctor, nurse or
pharmacist can result in improved adherence to second-
ary prevention CVD medications.
There is high-quality evidence to support use of
aspirin, ACEIs/ARBs, β blockers and statins in secondary
prevention of CVD.9 42 However, a recent analysis of
Cochrane reviews and RCTs in non-communicable dis-
eases (including CVD) showed that almost 90% of trials
and over 80% of participants were from high-income
countries,43 and our analysis further highlights the
sparse data for policymakers to make evidence-based
changes to improve adherence to secondary prevention
medications for CVD, particularly in low-income settings.
The overall quality of evidence is low by objective cri-
teria,44 due to lack of directness of evidence, heterogen-
eity across studies and only 12 (48%) of the 25 included
studies being RCTs. There were no studies in low-income
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countries and only one study in an upper
middle-income country, and two studies included a
lower middle-income country.20 24 Moreover, there were
neither quantitative studies regarding physical resources
and social resources nor qualitative studies of adherence
to secondary CVD prevention medications. As well as
limited study numbers, heterogeneity in study design,
study populations, study quality, health system arrange-
ments and outcomes make meta-analysis and synthesis
of the available data extremely challenging. Given the
lack of large-scale and generalisable data to support
changes in health systems to improve adherence to med-
ications for CVD, policymakers can take advantage of
context-speciﬁc information, including quantitative data.
We were unable to ﬁnd any qualitative studies meeting
our inclusion criteria, but this particular study design
may be informative in understanding local context for
patients, healthcare providers and policymakers.
The imbalance between efﬁcacy research (eg, pharma-
cologic trials with ‘hard’ clinical outcomes) and policy-
oriented implementation research (eg, adherence) is
well documented in CVD and other diseases.45–47 The
World Heart Federation’s Roadmap has emphasised the
“‘treatment effectiveness cascade’ from the cardiovascu-
lar event to the long-term adherence with priority inter-
ventions”.12 This systematic review illustrates that,
particularly in low-income settings, the understanding of
health system barriers and facilitators is poor from a
research perspective, and that practical research and
pragmatic solutions are urgently required, if the World
Heart Federation’s goals of reducing premature CVD
mortality by at least 25% by 2025 are to be fulﬁlled.
Poor adherence to prescribed therapy has been esti-
mated to account for at least 9% of CVD events in
Europe alone,48 and optimal adherence is associated
with better outcomes in CVD.49 Importantly, FDC
therapy has been shown to improve adherence in other
diseases including hypertension50 and HIV/AIDS.51
FDC therapy may improve adherence in CVD secondary
prevention on the basis of four trials,20 25 26 28 but the
results of several other trials are awaited and there is still
uncertainty whether FDC therapy inﬂuences long-term
outcomes.25 52 There are concerns regarding the exact
combination and dose of medications in FDC therapy, as
shown by variations in combinations used in the trials
included in our review, but this strategy may standardise
supply and use of the component medications,53 leading
to calls for its inclusion in the WHO essential medicines
list.54
The secondary prevention medications investigated in
this review are off-patent and likely to be the most widely
available medications for treatment of CVD. However,
we show that lower or no copayment was still associated
with higher adherence to therapy in CVD, as illustrated
by previous analyses.55 56 These ﬁndings echo the con-
clusions of prior analyses of health system ﬁnancing in
other disease areas,57 suggesting as with FDC therapy,
that in the ﬁeld of adherence to CVD drug therapy,
there is scope for research, practice and policy to cross
disease boundaries, especially in low-income countries.
Universal healthcare coverage has been emphasised in
the sustainable development goals,58 offering opportun-
ities and challenges to embed full prescription coverage
for secondary prevention for CVD in cross-sectoral
approaches, which research and global health player
must embrace.
Global shortage of health workers is a threat to provi-
sion of healthcare including CVD prevention.59 The
ﬁnding that counselling of patients, regardless of the
profession of the health worker, can result in improved
adherence to secondary prevention CVD medications
has signiﬁcance in the context of international debate
about universal health coverage and task shifting of
health workers. Unlike other disease areas, the imple-
mentation of task-shifting strategies for CVD is lacking in
an evidence base in low-income settings,60 and this
should be a focus of future research in secondary CVD
prevention and improvement strategies for medication
adherence.
Limitations
This study, like any systematic review, was limited by
inclusion criteria, and we restricted our study to second-
ary prevention medications for CVD. The initiation and
use of medications was not studied, only studies of
adherence and persistence were included and therefore
not all barriers and facilitators to appropriate medica-
tion use were investigated in this analysis. Only pub-
lished literature was considered. We were able to include
only 25 studies in our systematic review as already dis-
cussed. The studies could not be weighted by relative
relevance of each of these results as they are context
limited. However, the interventions recommended by
this review are unlikely to be dependent on context.
Meta-analysis was not possible due to heterogeneity in
several respects. We did not assess conﬂict of interest.
Conclusions with respect to particular barriers and facili-
tators, drug class and persistence versus adherence were
limited by the number of studies available.
Generalisability of ﬁndings is questionable, suggesting
that a common methodology for studies of medication
adherence (and persistence) in CVD and other diseases
is required, as well as urgent need for research in low-
income settings.
CONCLUSIONS
To the best of our knowledge, this is the ﬁrst systematic
review of health system inﬂuences on adherence to
evidence-based secondary prevention therapies in CVD.
Lack of generalisable, high-quality evidence to inform
policy to improve adherence highlights the pressing
need for research, particularly in low-income countries.
Full prescription coverage and reduced copayments,
FDC therapy and patient counselling are supported by
existing literature as strategies to improve adherence
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and are priorities for further research before implemen-
tation. Standardised deﬁnitions of and approaches to
adherence and persistence are also required in consen-
sus guidelines for management of CVD.
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